Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-03-05FDA Approved: METHYLPHENIDATE HYDROCHLORIDE (LA) — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved Dr. Reddy's Laboratories' supplemental application for methylphenidate hydrochloride long-acting (LA), a generic ADHD medicatio…
-
CLINICAL_TRIALS trial_result · 2016-03-01Clinical Trial Update: ERP Based Single-dose Predictions of Stimulants [Phase 2]
Phase 2 ERP-based study evaluating single-dose predictions of stimulants for ADHD has completed.
-
CLINICAL_TRIALS trial_result · 2016-02-25Clinical Trial Update: Role of Transcranial Direct Current Stimulation (tDCS) in Patients With Attention Deficit Hyperactivity Disorder (ADHD) [NA]
A clinical trial evaluating transcranial direct current stimulation for attention deficit hyperactivity disorder has completed; outcome deta…
-
CLINICAL_TRIALS trial_result · 2016-02-19Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD). [Phase 2]
Phase 2 study evaluating two doses of PF-03654746 for attention deficit hyperactivity disorder in adults completed, with results posted.
-
FDA approval · 2016-02-16FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved an original application for a generic mixed amphetamine salts product (dextroamphetamine and amphetamine salts) from Amneal Pha…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-02-09FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for methylphenidate from Sandoz Inc, resulting in an expanded/updated authorization for the product.
-
CLINICAL_TRIALS trial_result · 2016-02-09Clinical Trial Update: Increasing Academic Success in Middle School Students With ADHD [NA]
The update reports completion of a trial evaluating behavioral therapy plus motivational interviewing to improve academic outcomes in middle…
-
CLINICAL_TRIALS trial_result · 2016-02-04Clinical Trial Update: Atomoxetine, Placebo and Parent Management Training in Autism [Phase 4]
Phase 4 study evaluating atomoxetine versus placebo in combination with parent management training for children with autism and related perv…
-
CLINICAL_TRIALS trial_result · 2016-02-03Clinical Trial Update: NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 3]
Phase 3 trial of NWP09 in children with ADHD has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2016-01-28Clinical Trial Update: The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 3]
Phase 3 trial assessing safety and efficacy of a compound natural health product in children with ADHD has completed.
-
FDA approval · 2016-01-27FDA Approved: AMPHETAMINE EXTENDED-RELEASE — Original Application (Neos Therapeutics, LP)
FDA approved AMPHETAMINE EXTENDED-RELEASE under an original NDA for the treatment of attention-deficit/hyperactivity disorder.
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Effectiveness Study of Videoconferencing on Teaching Parent Training Skills to Parents of Children With Attention Deficit Hyperactivity Disorder (ADHD) [NA]
A completed clinical trial evaluating whether videoconferencing can effectively teach parent training skills to parents of children with Att…
-
FDA approval · 2015-12-28FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for a generic dexmethylphenidate hydrochloride product from Amneal Pharmaceuticals of New York L…
-
CLINICAL_TRIALS research · 2015-12-22Clinical Trial Update: Randomized Controlled Trial With Use of Cognitive Training in Children and Adolescents With ADHD [NA]
This record outlines a randomized controlled trial evaluating cognitive training for children and adolescents with Attention-deficit/hyperac…
-
FDA approval · 2015-12-21FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved an original ANDA for dexmethylphenidate hydrochloride from Amneal Pharmaceuticals of New York LLC.
-
CLINICAL_TRIALS trial_result · 2015-12-18Clinical Trial Update: Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD) [NA]
A completed clinical trial from Indiana University evaluating computer-assisted methods for diagnosing and treating Attention Deficit Hypera…
-
CLINICAL_TRIALS research · 2015-12-09Clinical Trial Update: Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD) [Phase 2, Phase 3]
An update on Phase 2 and Phase 3 ADHD trials led by R. van Mourik, with the studies listed as completed.
-
CLINICAL_TRIALS trial_result · 2015-12-09Clinical Trial Update: AR08 for Treatment of ADHD in Children [Phase 2]
A Phase 2 trial update for AR08 in treating ADHD in children has completed.
-
CLINICAL_TRIALS research · 2015-12-07Clinical Trial Update: Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers [Phase 4]
This document provides an update on a Phase 4 clinical trial at a Translational Center for identifying ADHD biomarkers. The sponsor is Seoul…
-
FDA approval · 2015-12-04FDA Approved: QUILLICHEW ER — Original Application (NextWave Pharmaceuticals, Inc)
FDA approved QUILLICHEW ER (methylphenidate hydrochloride) through an original NDA submitted by NextWave Pharmaceuticals, Inc.
-
FDA approval · 2015-12-04FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) from Sandoz Inc.
-
FDA label_change · 2015-12-04FDA Approved: FOCALIN — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for FOCALIN (dexmethylphenidate hydrochloride) submitted by Sandoz Inc, resulting in a label cha…
-
FDA approval · 2015-12-04FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2015-12-04FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (KVK-TECH, INC)
FDA approves the original application for dexmethylphenidate hydrochloride tablets from KVK-Tech, Inc., establishing its use as a generic tr…
-
FDA approval · 2015-12-04FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' original application for a generic dexmethylphenidate hydrochloride product intended for ADHD.